HC Wainwright Issues Pessimistic Forecast for LBRX Earnings

LB Pharmaceuticals Inc (NASDAQ:LBRX) – Investment analysts at HC Wainwright reduced their FY2026 EPS estimates for shares of LB Pharmaceuticals in a note issued to investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($5.98) per share for the year, down from their prior estimate of ($5.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($5.87) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q4 2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($1.57) EPS, Q2 2027 earnings at ($1.33) EPS, Q3 2027 earnings at ($1.24) EPS, Q4 2027 earnings at ($1.30) EPS and FY2027 earnings at ($5.44) EPS.

LBRX has been the subject of several other reports. Piper Sandler reissued an “overweight” rating and set a $78.00 price target on shares of LB Pharmaceuticals in a report on Monday, August 3rd. Zacks Research lowered LB Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, October 12th. Canaccord Genuity Group started coverage on LB Pharmaceuticals in a research report on Friday, October 9th. They set a “buy” rating and a $65.00 price objective on the stock. Stifel Nicolaus set a $53.00 target price on LB Pharmaceuticals in a report on Thursday, August 13th. Finally, Wall Street Zen cut shares of LB Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Sunday. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.40.

LB Pharmaceuticals Trading Down 0.4%

LB Pharmaceuticals stock opened at $44.94 on Wednesday. LB Pharmaceuticals has a 12 month low of $14.32 and a 12 month high of $50.16. The stock’s 50 day moving average is $40.47 and its 200-day moving average is $33.17. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -9.73 and a beta of 0.82.

LB Pharmaceuticals (NASDAQ:LBRX) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by ($0.18).

Institutional Investors Weigh In On LB Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Calamos Advisors LLC bought a new stake in shares of LB Pharmaceuticals in the first quarter valued at approximately $593,000. Great Lakes Advisors LLC bought a new position in LB Pharmaceuticals during the 2nd quarter worth $987,000. Profund Advisors LLC bought a new position in LB Pharmaceuticals during the 3rd quarter worth $1,082,000. Bank of New York Mellon Corp raised its holdings in LB Pharmaceuticals by 12.2% in the 1st quarter. Bank of New York Mellon Corp now owns 45,457 shares of the company’s stock valued at $1,121,000 after acquiring an additional 4,940 shares in the last quarter. Finally, Sigma Planning Corp acquired a new position in LB Pharmaceuticals in the 3rd quarter valued at $1,151,000.

LB Pharmaceuticals Company Profile

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company’s lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.